
Vectura asthma treatment fails at Phase III
pharmafile | August 30, 2016 | News story | Manufacturing and Production, Research and Development | asthma, inhaler, phase III, phase III failure, vectura
Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted by European partner Mundipharma.
The inhaler failed to show a “statistically significant” superiority in reducing the yearly degradation of moderate to severe chronic obstructive pulmonary disease (COPD) compared to mono-component LABA treatment.
1,767 randomly selected patients from 16 countries took part in Phase III of the trial, a double-blind study comparing Flutiform to Formoterol Fumarate Dihydrate, a treatment for COPD including chronic bronchitis.
The company has reported that Mundipharma are still in the process of analysing the trial’s other endpoints, but the failure of its primary objective means it will not be filing a regulatory request for the treatment in Europe.
“Whilst this result is disappointing, Flutiform continues to grow strongly based on the approved asthma indication, which continues to underpin our expectations for future growth of the product,” commented CEO James Ward-Lilley.
The company was nevertheless the biggest loser at the London Stock Exchange on Tuesday, with shares down 10% to 124.8p.
Matt Fellows
Related Content

1nhaler receives £1.5m in funding to develop new cardboard inhaler
1nhaler, a Scotland-based developer of drug delivery devices, has received £1.5m in seed funding for …

GSK shares positive results from phase 3 asthma trials
GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which …

GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trials
GSK has announced that in 2024 it intends to start phase 3 trials of a …






